Critical size limit of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration
- 148 Downloads
Lymph node (LN) targeting through interstitial drainage of nanoparticles (NPs) is an attractive strategy to stimulate a potent immune response, as LNs are the primary site for lymphocyte priming by antigen presenting cells (APCs) and triggering of an adaptive immune response. NP size has been shown to influence the efficiency of LN-targeting and retention after subcutaneous injection. For clinical translation, biodegradable NPs are preferred as carrier for vaccine delivery. However, the selective “size gate” for effective LN-drainage, particularly the kinetics of LN trafficking, is less well defined. This is partly due to the challenge in generating size-controlled NPs from biodegradable polymers in the sub-100-nm range. Here, we report the preparation of three sets of poly(lactic-co-glycolic)-b-poly(ethylene-glycol) (PLGA-b-PEG) NPs with number average diameters of 20-, 40-, and 100-nm and narrow size distributions using flash nanoprecipitation. Using NPs labeled with a near-infrared dye, we showed that 20-nm NPs drain rapidly across proximal and distal LNs following subcutaneous inoculation in mice and are retained in LNs more effectively than NPs with a number average diameter of 40-nm. The drainage of 100-nm NPs was negligible. Furthermore, the 20-nm NPs showed the highest degree of penetration around the paracortex region and had enhanced access to dendritic cells in the LNs. Together, these data confirmed that small, size-controlled PLGA-b-PEG NPs at the lower threshold of about 30-nm are most effective for LN trafficking, retention, and APC uptake after s.c. administration. This report could inform the design of LN-targeted NP carrier for the delivery of therapeutic or prophylactic vaccines.
Keywordsbiodegradable nanoparticle lymph node trafficking vaccine delivery nanoparticle size antigen presenting cells in vivo imaging
Unable to display preview. Download preview PDF.
This work was funded by support from the National Institutes of Health (Nos. R01-AI114609 and T32-OD11089) and NSF GRFP (No. DGE1746891). Partial support was received from the University of Florida Emerging Pathogens Institute.
- Mottram, P. L.; Leong, D.; Crimeen-Irwin, B.; Gloster, S.; Xiang, S. D.; Meanger, J.; Ghildyal, R.; Vardaxis, N.; Plebanski, M. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: Formulation of a model vaccine for respiratory syncytial virus. Mol. Pharm. 2007, 4, 73–84.CrossRefGoogle Scholar
- Zheng, S. S.; Qin, T.; Lu, Y.; Huang, Y. F.; Luo, L.; Liu, Z. G.; Bo, R. N.; Hu, Y. L.; Liu, J. G.; Wang, D. Y. Maturation of dendritic cells in vitro and immunological enhancement of mice in vivo by pachyman-and/or OVA-encapsulated poly(D, L-lactic acid) nanospheres. Int. J. Nanomedicine 2018, 13, 569–583.CrossRefGoogle Scholar
- Maldonado, R. A.; LaMothe, R. A.; Ferrari, J. D.; Zhang, A. H.; Rossi, R. J.; Kolte, P. N.; Griset, A. P.; O’Neil, C.; Altreuter, D. H.; Browning, E. et al. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. USA 2015, 112, E156–E165.CrossRefGoogle Scholar